Genomic Determinants of Intrinsic Antiviral Host Defenses
Genomic Determinants of Intrinsic Antiviral Host Defenses
批准号:
8277253
负责人:
Viviana A Simon
金额:
$42.62万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-06-01 至 2015-05-31
关键词:
AIDS/HIV problemAcquired Immunodeficiency SyndromeAffectAfricanAfrican AmericanAgreementAntiviral AgentsArchitectureAsiansBiological AssayBiological MarkersCell LineCellsClinicCodeCommunitiesComplementCopy Number PolymorphismCytidine DeaminaseDNADataDeaminaseDendritic CellsDiseaseDisease ProgressionEpidemiologic StudiesEuropeanEventExonsFamilyFemaleFluorescent in Situ HybridizationFutureGene DuplicationGene ExpressionGene FamilyGenesGenetic TranscriptionGenetic VariationGenomicsGenotypeGoalsHIV-1Half-LifeHaplotypesHispanicsHost DefenseHumanHuman GeneticsImmune responseImmunoblottingImmunologistIn VitroIndividualInfectionIntegration Host FactorsInterferon Type IInvestigationKnowledgeLeadLigandsLinkLymphocyteMapsMethodologyModelingMolecular VirologyPathogenesisPatientsPatternPhenotypePlant RootsPopulationPredispositionPropertyProteinsPublishingRegulationReportingResearch PersonnelResistanceResolutionRetroviridaeRiskRoleSamplingScreening procedureSingle Nucleotide PolymorphismStructureStructure-Activity RelationshipSystemT-LymphocyteTechnologyTestingTimeTranscriptTranscriptional RegulationTransfectionVariantViralcohortcomparative genomic hybridizationcost effectivedosageenzyme structureexperiencegene complementationgene functiongenome-widein vivoinsertion/deletion mutationinsightmRNA Expressionmonocytenext generationnovelpopulation basedpressureprotein expressionpublic health relevanceresearch studyresponsestructural genomicstooltreatment strategy
中文摘要
描述(由申请人提供):对HIV-1感染的易感性在不同的人之间有很大的差异,疾病的进展率不仅由病毒的特性决定,而且由宿主因素决定。这一建议的中心假设是APOBEC3(A3)限制因子家族的广泛多样化导致了HIV-1在体内复制的高度可变性。越来越多的证据表明,基因组变异--从单核苷酸多态(SNPs)到大的结构变异--影响宿主抗病毒防御的效果。事实上,我们有证据表明,自然产生的SNPs可以调节A3F和A3H的抗病毒活性。此外,我们还确定了A3基因座附近和内部的三个区域,这些区域显示了HapMap群体之间的拷贝数差异(基于450名西非、亚洲和欧洲血统的个体的数据)。这些拷贝数变异体(CNV)与A3B、A3E和A3F外显子重叠,并可能与APOBEC基因座的上游调控序列重叠。初步数据表明,HIV-1感染的长期无进展者(LTNP)的APOBEC基因座富含A3拷贝数变异,提示A3拷贝数变异具有保护作用。相反,我们已经证明了A3-CNV2拷贝丢失(A3B基因完全缺失)的纯合子细胞在体外更容易感染HIV-1。总体而言,我们的初步数据强烈支持这样的概念,即A3区域在结构上是多态的,由此产生的A3变异对HIV-1复制产生关键影响。在特定的目标1(CNV发现和定位)中,我们将使用尖端技术以非常高的分辨率询问A3基因家族簇,以捕获嵌入该基因座的广泛的CNV。为此,我们将使用来自不同种族(18个不同群体)或表型选择(LTNP)人群的样本。在特定的目标2(基因表达)中,我们将确定A3-CNV基因型特有的mRNA表达模式,并确定与重排的A3基因座相关的蛋白质变体。我们还将比较LTNPs和治疗进展者的淋巴细胞和树突状细胞中A3基因组变体的转录调控。在特定的目标3(基因功能)中,将使用来自已知A3基因类型的个体的淋巴细胞以及表达代表自然循环的A3基因组变体的基因产物的模型细胞系来测试A3-CNvs和SNPs对病毒限制的影响。这些实验将结合A3区域的基因组变异数据,了解A3脱氨酶的调节和抗病毒功能。这项对A3基因组结构高度变异性的功能后果的全面调查应有助于确定新的生物标记物,以便在未来的逆转录病毒感染流行病学研究中进行测试。此外,了解内在防御因子的功能多样性有可能创造新的治疗策略,旨在长期抑制艾滋病毒/艾滋病。
公共卫生相关性:对艾滋病毒-1感染和艾滋病进展的易感性在不同的人之间有很大差异。这项建议的目的是确定APOBEC 3基因座内结构基因组变异的程度,并评估这些内在耐药基因的变异如何影响HIV-1复制。
英文摘要
DESCRIPTION (provided by applicant): Susceptibility to HIV-1 infection varies greatly between individuals, with disease progression rates determined not only by viral properties but also host factors. The central hypothesis of this proposal is that the extensive diversification of the APOBEC3 (A3) family of restriction factors contributes to the high degree of variability in HIV-1 replication in vivo. There is growing evidence that genomic variation - ranging from single nucleotide polymorphisms (SNPs) to large structural variants - influences the efficacy of host antiviral defenses. Indeed, we have evidence that naturally occurring SNPs modulate the antiviral activity of A3F and A3H. Moreover, we have identified three regions near and within the A3 locus itself that show copy number variations among HapMap populations (based on data from 450 individuals of West-African, Asian and European ancestry). These copy number variants (CNV) overlap with A3B, A3E and A3F exons and possibly upstream regulatory sequences of the APOBEC locus. Preliminary data indicate that the APOBEC loci from HIV-1 infected long-term non-progressors (LTNP) are enriched for A3 copy number variants, suggesting a protective role of A3 copy number variation. Conversely, we have shown that cells homozygous for A3-CNV2 copy loss (complete deletion of the A3B gene) are more susceptible to HIV-1 infection in vitro. Collectively, our preliminary data strongly support the notion that A3 regions are structurally polymorphic and that the resulting A3 variants exert a key impact on HIV-1 replication. In specific aim 1 (CNV discovery and mapping), we will interrogate the A3 gene family cluster at very high resolution using cutting edge technologies to capture the wide range of CNVs embedded in this locus. For this purpose, we will use samples from ethnically diverse (18 different groups) or phenotypically selected (LTNP) populations. In specific aim 2 (gene expression), we will determine the mRNA expression pattern specific for A3-CNV genotypes and identify protein variants associated with the panel of rearranged A3 loci. We will also compare the transcriptional regulation of A3 genomic variants in lymphocytes and dendritic cells of LTNPs and treated progressors. In specific aim 3 (gene function), the impact of A3-CNVs and SNPs on viral restriction will be tested, using lymphocytes from individuals with known A3 genotypes, as well as model cell-lines expressing gene products representing naturally circulating A3 genomic variants. These experiments will integrate genomic variation data of the A3 region with an understanding of the regulation and antiviral functions of A3 deaminases. This comprehensive investigation into the functional consequences of the high variability in A3 genomic architecture should help identify new biomarkers to be tested in future epidemiological studies of retroviral infections. In addition, understanding the functional diversity of intrinsic defense factors has the potential to create novel treatment strategies aimed at a long- lasting suppression of HIV/AIDS disease.
PUBLIC HEALTH RELEVANCE: Susceptibility to HIV-1 infection and AIDS disease progression varies greatly among individuals. The goal of this proposal is to determine the degree of structural genomic variation within the APOBEC 3 locus, and to assess how variability of these intrinsic resistance genes impacts on HIV-1 replication.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Administrative Core
-
批准号:10549476
-
项目类别:
-
资助金额:$25.35万
-
财政年份:2023
-
负责人:Viviana A Simon
-
依托单位:
Understanding antibody responses and defining correlates of protection for endemic and pandemic coronavirus strains
-
批准号:10549479
-
项目类别:
-
资助金额:$104.19万
-
财政年份:2023
-
负责人:Viviana A Simon
-
依托单位:
Dissecting the drivers of persistent SARS-CoV-2 infections
-
批准号:10736007
-
项目类别:
-
资助金额:$83.13万
-
财政年份:2023
-
负责人:Viviana A Simon
-
依托单位:
Clinical Core
-
批准号:10435233
-
项目类别:
-
资助金额:$28.32万
-
财政年份:2022
-
负责人:Viviana A Simon
-
依托单位:
HIV latency driven microgliosis
-
批准号:10700148
-
项目类别:
-
资助金额:$21.13万
-
财政年份:2022
-
负责人:Viviana A Simon
-
依托单位:
HIV latency driven microgliosis
-
批准号:10618696
-
项目类别:
-
资助金额:$25.35万
-
财政年份:2022
-
负责人:Viviana A Simon
-
依托单位:
Clinical Core
-
批准号:10595625
-
项目类别:
-
资助金额:$27.71万
-
财政年份:2022
-
负责人:Viviana A Simon
-
依托单位:
Preventing CD4+ T memory cells from becoming HIV reservoirs
-
批准号:9914204
-
项目类别:
-
资助金额:$59.33万
-
财政年份:2018
-
负责人:Viviana A Simon
-
依托单位:
Targeting HIV persistence in CD4+ T memory stem cells
-
批准号:9321252
-
项目类别:
-
资助金额:$42.38万
-
财政年份:2016
-
负责人:Viviana A Simon
-
依托单位:
HTLV-1 antagonists of HIV restriction factors
-
批准号:8651884
-
项目类别:
-
资助金额:$21.01万
-
财政年份:2013
-
负责人:Viviana A Simon
-
依托单位:
HTLV-1 antagonists of HIV restriction factors
-
批准号:8466151
-
项目类别:
-
资助金额:$25.24万
-
财政年份:2013
-
负责人:Viviana A Simon
-
依托单位:
Genomic Determinants of Intrinsic Antiviral Host Defenses
-
批准号:8470533
-
项目类别:
-
资助金额:$40.07万
-
财政年份:2010
-
负责人:Viviana A Simon
-
依托单位:
Genomic Determinants of Intrinsic Antiviral Host Defenses
-
批准号:8660599
-
项目类别:
-
资助金额:$42.61万
-
财政年份:2010
-
负责人:Viviana A Simon
-
依托单位:
Genomic Determinants of Intrinsic Antiviral Host Defenses
-
批准号:8012140
-
项目类别:
-
资助金额:$44.75万
-
财政年份:2010
-
负责人:Viviana A Simon
-
依托单位:
Genomic Determinants of Intrinsic Antiviral Host Defenses
-
批准号:8075524
-
项目类别:
-
资助金额:$42.61万
-
财政年份:2010
-
负责人:Viviana A Simon
-
依托单位:
HIV-1 evolution driven by intracellular defenses
-
批准号:7846471
-
项目类别:
-
资助金额:$1.7万
-
财政年份:2009
-
负责人:Viviana A Simon
-
依托单位:
HIV-1 evolution driven by intracellular defenses
-
批准号:7069062
-
项目类别:
-
资助金额:$5.59万
-
财政年份:2005
-
负责人:Viviana A Simon
-
依托单位:
HIV Evolution Driven by Intracellular Defenses
-
批准号:8697000
-
项目类别:
-
资助金额:$61.93万
-
财政年份:2005
-
负责人:Viviana A Simon
-
依托单位:
HIV-1 evolution driven by intracellular defenses
-
批准号:7006413
-
项目类别:
-
资助金额:$34.48万
-
财政年份:2005
-
负责人:Viviana A Simon
-
依托单位:
HIV-1 evolution driven by intracellular defenses
-
批准号:7369738
-
项目类别:
-
资助金额:$35.47万
-
财政年份:2005
-
负责人:Viviana A Simon
-
依托单位:
海外基金